Contact Us

The Migraine Relief Study: Chicago - Milwaukee Region. Chronic Migraine, Chronic Daily Headache and Hemicrania Continua Relief and Sphenopalatine Ganglion (SPG) Blocks

A New Medical Study, "The Migraine Relief Study" is designed to Evaluate objective and subjective response of patients with severe continual headache that has been resistant to other medical treatments. Sphenopalatine Ganglion Blocks to be Evaluated
    CHICAGO, IL, July 12, 2016 /24-7PressRelease/ -- Chronic Migraine, Chronic Daily Headache and Hemicrania Continua: New Study on stopping the cycle of pain is seeking subjects with chronic daily headache, hemicrania continua and migraine pain resistant to other treatments.

A New Medical Study, "The Migraine Relief Study" is designed to Evaluate objective and subjective response of patients with severe continual headache that has been resistant to other medical treatments.

This initial study is for patients with continual headache for 30 days or more and requires a single visit at which surface EMG studies before and after treatment will be obtained. The procedure has been previously shown to be effective for headaches, migraines,anxiety, depression and other chronic pain conditions and is not considered experimental.

A simple headache severity diary is requested for one month following treatment. This is essential in all patients. The study location is in Highland Park, Illinois. There is ample free parking available and the office is conveniently located near a Metra station for Chicago and Milwaukee patients who do not drive.

Each patient will do a 1-2 minute video prior to starting treatment and a follow-up video on the same day after treatment.

There is no control group in the initial study so all participants will receive active treatment.

Requirements;
1.Previous Diagnosis of CDH, HC, or Migraine from physician or ideally neurologist
2. Male or Female patients are welcome
3. Patients cannot be pregnant.
4. No known allergies to Lidocaine anesthetic.
5. This study is for patients with head and neck pain but does not exclude disorders affecting the whole body such as Fibromyalgia
6. Injections are part of this study
7. Sphenopalatine Ganglion Blocks will be administered to each patient.
8. Patients will be present in the office with other patients participating in this study. Patients who feel this is not acceptable may still be considered but will not be part of initial day of testing.

Patients interested in this study should respond to "The Migraine Relief Study" at MigraineReliefStudy@gmail.com.

Study is closed. Please contact Dr Shapira thru www.ThinkBetterLife.com

We will need both an e-mail address and phone number associated with each patient.

A short history of headaches, when they started, precipitating events and previous treatments that have been tried and how they worked. A rating on scale of 1-10, 10 being most severe headaches, typical daily headache, and "best days" and "worst days". A short description of each in the patients own words.

A short statement of how these headaches have affected your life.

There is no payment to patients for participating. There are no costs to patients or to patients insurance companies. Ideally these results will be used to demonstrate how insurance companies can help patients seeking a better quality of treatment while reducing medical costs to patients and insurance companies.

Ideally, there is an expectation that this block will break the cycle of pain in many patients, in essence "Rebooting the Brain" There are no guarantee of successful elimination of pain.

The results will be used in a scientific presentation.

This is only a one-time study and does not include follow-up treatment. Results of the study will be made available to all participants upon request.

#sphenopalatineganglionblocks, #spgblocks #migrainereliefstudy, chronicdailyheadacherelief,
#chicagomigrainestudy, #migraineclinicalresearch #chronicdailyheadachesclinicalresearch, chicagospgblock, #chicagosphenopalatineganglonblocks

The Migraine Headache Relief Study will be presented to the International College of CranioMandibular Orthopedics and will utilize objective EMG measurements of trigeminally innervated muscles to evaluate the effects of SPG Blocks.

Dr Shapira is the founder of Chicagoland Dental Sleep Medicine and the study will be done in his office at 3500 Western Ave in Highland Park.

Dr Shapira treats chronic head and neck pain, TMJ disorders and trigeminally innervated headaches and migraines in this office in addition to sleep apnea and other sleep disorders.

Dr Ira L Shapira created the I HATE CPAP (www.ihatecpap.com) and I HATE HEADACHE (www.ihateheadaches.org) websites to help patients find help with these difficult medical disorders that medicine can frequently not treat adequately without a dental collaboration. Dr Shapira did research in the 1980's as a visiting assistant professor at Rush Medical School where he worked with Rosalind Cartwright PhD who is primarily responsible for the entire field of Dental Sleep Medicine. He also studied with Dr Barney Jankelson who created the initial concepts that neuromuscular dentistry still uses today and created a company Myotronics that is the leading manufacturer of instrumentation used by Neuromuscular Dentistry.

Dr Shapira is a Diplomate of The American Board of Dental Sleep Medicine, a Diplomate of the American Academy of Pain Management, and a Fellow of the International College of CranioMandibular Orthopedics (ICCMO). He is a former national and International Regent of ICCMO, its current Secretary and the representative to the Alliance of TMD organizations or the TMD ALLIANCE has a general dental practice (http://www.delanydentalcare.com) in Gurnee, Il and has recently started Chicagoland Dental Sleep Medicine Associates with offices in Vernon Hills and Highland Park. Patients in Northern Illinois or southern Wisconsin can contact Dr Shapira thru his office websites or thru http://www.ihateheadaches.org or http://www.chicagoland.ihatecpap.com www.ThinkBetterLife.com, NorthShoreSleepDentist.com SleepandHealth.com

Dr Ira L Shapira is President of I HATE CPAP LLC, President Dato-TECH, and has a Dental Practice, Delany Dental Care with his partner Dr Mark Amidei. He has recently formed Chicagoland Dental Sleep Medicine Associates. He is a Regent of ICCMO and its representative and the current Chair of the American Alliance of TMD Organizatins (www.TMDAlliance.com), He was a founding and certified member of the Sleep Disorder Dental Society which became the American Academy of Dental Sleep Medicine, A founding member of DOSA the Dental Organization for Sleep Apnea. He is a Diplomate of the American Board of Dental Sleep Medicine, A Diplomat of the American Academy of Pain Management, a graduate of LVI. He is a former assistant professor at Rush Medical School's Sleep Service where he worked with Dr Rosalind Cartwright who is a founder of the fields of Sleep Medicine and Dental Sleep Medicine. Dr Shapira is a consultant to numerous sleep centers and teaches courses in Dental Sleep Medicine in his office to doctors from around the U.S. He is the Founder of I HATE CPAP LLC and http://www.ihatecpap.com

Dr Shapira also holds several patents on methods and devices for the prophylactic minimally invasive early removal of wisdom teeth and collection of bone marrow and stem cells. He is currently working with Dr Tom Diekwisch at the Baylor in Texas to prove these stem cells can change peoples lives for the better. Dr Shapira is a licensed general dentist in Illinois and Wisconsin.

Dr Shapira is currently working on patents he hope will drastically improve the field of pain management.


# # #

Read more Press Releases from Ira Shapira:


Comment on this story...

Share This Story


Email this Story

Contact Information


Ira Shapira
Sleep and Health Journal

Highland Park, Illinois
United States
Voice: 847-533-8313
E-Mail: Email Us Here
Website: Visit Our Website
Blog: Visit Our Blog

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.